Cyxone AB (CYXO) Introduced at the online HC Andersen Capital event on 29 April

Cyxone’s CEO Tara Heitner will present an introduction to the company on Friday 29 April 2022 at 11.00-11.30 at the digital HC Andersen Capital event. It will be possible to ask questions during the presentation, which will be held in English.

To register, please use the link: https://hcandersencapital643.clickmeeting.com/cyxone-introduction-to-the-share/register

To follow the event: https://www.linkedin.com/events/6923251014040985601/about/

Contact

Tara Heitner, CEO
Tel: +46 (0)70 781 88 08
Email: tara.heitner@cyxone.com

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. For more information, please visit www.cyxone.com